13 Best Healthcare Stocks to Buy Under $10
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics.
Biocryst Pharmaceuticals Inc (BCRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 8,928,523 | $66,963,923 | -2% | 5.63% |
| 2. | VenBio Select Advisor Kurt Von Emster | 8,700,000 | $65,250,000 | -27% | 1.02% |
| 3. | Alkeon Capital Management Panayotis Takis Sparaggis | 7,214,021 | $54,105,158 | +2% | 0.11% |
| 4. | Deerfield Management James E. Flynn | 5,189,665 | $38,922,488 | -37% | 0.77% |
| 5. | Millennium Management Israel Englander | 3,812,874 | $28,596,555 | +383% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.36 | 7,861 | $49,995.96 | 44,951 | 2024-05-30 | Filing | |
| $6.40 | 2,500 | $16,000.00 | 2,500 | 2024-05-24 | Filing | |
| $6.38 | 5,000 | $31,900.00 | 86,818 | 2024-05-20 | Filing | |
| $6.25 | 15,000 | $93,750.00 | 66,997 | 2024-05-20 | Filing | |
| $5.57 | 36,300 | $202,191.00 | 266,744 | 2024-05-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.54 | 7,000 | $52,780.00 | 86,638 | 2024-12-13 | Filing | |
| $6.32 | 8,600 | $54,352.00 | 27,831 | 2024-06-24 | Filing | |
| $6.00 | 4,689 | $28,134.00 | 27,742 | 2024-06-17 | Filing | |
| $6.11 | 6,698 | $40,924.78 | 52,852 | 2024-06-14 | Filing | |
| $7.98 | 4,000 | $31,920.00 | 25,611 | 2023-06-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,620,637 | $32,440,908 | 0.05% | |
| 2. | 274,328 | $2,457,979 | 0.67% | |
| 3. | 46,163 | $413,620 | 0.04% | |
| 4. | 37,766 | $337,628 | 0% | |
| 5. | 14,079 | $126,148 | 0% |
News See All
BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call Transcript
Operator: Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode.
10 Best Small-Cap Stocks to Buy Now
The S&P 500 index has reached its all-time highs, achieving returns of over 20% for two second consecutive years post-COVID.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript February 24, 2025BioCryst Pharmaceuticals, Inc. misses on earnings expectations.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript
Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.
Piper Sandler's Top Technical Stock Picks: 20 Best Stocks
The start of October has seen another wild swing for markets. September's second half saw Wall Street rejoice as the Federal Reserve delivered its highly anticipated interest rate cut.
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript August 5, 2024BioCryst Pharmaceuticals, Inc. beats earnings expectations.
Billionaire Hedge Funds
